Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Written informed consent.~2. Male or female between the ages of 18 and 75 years, inclusive, at Screening.~3. Meets the 2013 American College of Rheumatology/European League Against Rheumatism classification criteria for SSc with a total score of ≥9 (Van den Hoogen et al., 2013).~4. Classified as having skin involvement proximal to the elbow and knee (diffuse cutaneous SSc subset by LeRoy and Medsger, 2001).~5. At the time of enrollment, less than or equal to 72 months (6 years) since the onset of the first SSc manifestation, other than Raynaud's phenomenon.~6. Skin thickening from SSc in the forearm suitable for repeat biopsy.~7. mRSS units ≥15 at Screening.~8. FVC ≥45% predicted at Screening, as determined by spirometry.~9. Willing and able to comply with the prescribed treatment protocol and evaluations for the duration of the trial.~Exclusion Criteria:~1. Positive for anti-centromere antibodies with the exception that subjects who are positive for both anti-centromere and anti-topoi

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- HZN-825 300 mg once daily (QD) (Type: EXPERIMENTAL): One set of 2 HZN-825 150mg tablets in the morning and one set of 2 placebo tablets in the evening.
- HZN-825 300 mg twice daily (BID) (Type: EXPERIMENTAL): One set of 2 HZN-825 150mg tablets in the morning and one set of 2 HZN-825 150mg tablets in the evening.
- Placebo (Type: PLACEBO_COMPARATOR): One set of 2 placebo tablets in the morning and one set of 2 placebo tablets in the evening.

Based on this trial design, predict the completion outcome and termination type (if applicable).